JP2019089762A5 - - Google Patents

Download PDF

Info

Publication number
JP2019089762A5
JP2019089762A5 JP2018219226A JP2018219226A JP2019089762A5 JP 2019089762 A5 JP2019089762 A5 JP 2019089762A5 JP 2018219226 A JP2018219226 A JP 2018219226A JP 2018219226 A JP2018219226 A JP 2018219226A JP 2019089762 A5 JP2019089762 A5 JP 2019089762A5
Authority
JP
Japan
Prior art keywords
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018219226A
Other languages
English (en)
Other versions
JP2019089762A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019089762A publication Critical patent/JP2019089762A/ja
Publication of JP2019089762A5 publication Critical patent/JP2019089762A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 式:
    22、
    28、
    IV、
    11、
    15、
    16、


    26、
    27、
    30、
    31、
    32、
    34、
    36、
    37、
    43、または
    44
    を有する化合物。
JP2018219226A 2013-03-13 2018-11-22 ベンゾオキサゼピン化合物の作製方法 Pending JP2019089762A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018044050A Division JP2018150298A (ja) 2013-03-13 2018-03-12 ベンゾオキサゼピン化合物の作製方法

Publications (2)

Publication Number Publication Date
JP2019089762A JP2019089762A (ja) 2019-06-13
JP2019089762A5 true JP2019089762A5 (ja) 2019-10-10

Family

ID=50241450

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015562108A Active JP6363120B2 (ja) 2013-03-13 2014-03-12 ベンゾオキサゼピン化合物の作製方法
JP2017135083A Active JP6442005B2 (ja) 2013-03-13 2017-07-10 ベンゾオキサゼピン化合物の作製方法
JP2018044050A Pending JP2018150298A (ja) 2013-03-13 2018-03-12 ベンゾオキサゼピン化合物の作製方法
JP2018153231A Active JP6663459B2 (ja) 2013-03-13 2018-08-16 ベンゾオキサゼピン化合物の作製方法
JP2018219226A Pending JP2019089762A (ja) 2013-03-13 2018-11-22 ベンゾオキサゼピン化合物の作製方法
JP2020032846A Pending JP2020114814A (ja) 2013-03-13 2020-02-28 ベンゾオキサゼピン化合物の作製方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2015562108A Active JP6363120B2 (ja) 2013-03-13 2014-03-12 ベンゾオキサゼピン化合物の作製方法
JP2017135083A Active JP6442005B2 (ja) 2013-03-13 2017-07-10 ベンゾオキサゼピン化合物の作製方法
JP2018044050A Pending JP2018150298A (ja) 2013-03-13 2018-03-12 ベンゾオキサゼピン化合物の作製方法
JP2018153231A Active JP6663459B2 (ja) 2013-03-13 2018-08-16 ベンゾオキサゼピン化合物の作製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020032846A Pending JP2020114814A (ja) 2013-03-13 2020-02-28 ベンゾオキサゼピン化合物の作製方法

Country Status (16)

Country Link
US (1) US9303043B2 (ja)
EP (3) EP3404032A3 (ja)
JP (6) JP6363120B2 (ja)
KR (3) KR101821468B1 (ja)
CN (2) CN108929333A (ja)
AR (1) AR095365A1 (ja)
AU (3) AU2014230812B2 (ja)
BR (1) BR112015020716A2 (ja)
CA (6) CA2948763C (ja)
HK (1) HK1215433A1 (ja)
IL (1) IL240793A0 (ja)
MX (1) MX2015011438A (ja)
NZ (1) NZ711192A (ja)
RU (2) RU2018109979A (ja)
SG (2) SG10201706760YA (ja)
WO (1) WO2014140073A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083640A1 (en) 2013-12-16 2016-10-26 F. Hoffmann-La Roche AG Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
US9650393B2 (en) 2015-07-02 2017-05-16 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
EP3317283B1 (en) 2015-07-02 2019-04-03 H. Hoffnabb-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
JP7036724B2 (ja) * 2016-07-29 2022-03-15 日本たばこ産業株式会社 ピラゾール-アミド化合物の製造方法
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR102537048B1 (ko) 2016-12-15 2023-05-26 에프. 호프만-라 로슈 아게 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노) 프로판아미드의 제조 방법
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
WO2000024720A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
CA2453113A1 (en) 2001-07-12 2003-01-23 Avecia Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
MXPA04002931A (es) * 2001-10-12 2005-04-11 Bayer Pharmaceuticals Corp Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad.
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2008051805A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
PT2084162E (pt) * 2006-10-23 2012-10-09 Sgx Pharmaceuticals Inc Triazoles bicíclicos como moduladores de proteína quinase
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
US8716483B2 (en) * 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2784078A1 (en) 2009-09-28 2014-10-01 F. Hoffmann-La Roche AG Benzoxepin pi3k inhibitor compounds and methods of use
RU2600927C2 (ru) * 2009-09-28 2016-10-27 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3k и способы применения
CA2778684A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
WO2012126901A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
NO3175985T3 (ja) * 2011-07-01 2018-04-28
BR112014028376A2 (pt) * 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção

Similar Documents

Publication Publication Date Title
JP2019089762A5 (ja)
JP2018150298A5 (ja)
JP2018168171A5 (ja)
JP2020515557A5 (ja)
JP2019194236A5 (ja)
JP2020040981A5 (ja)
JP2020534795A5 (ja)
JP2017186358A5 (ja)
JP2012107057A5 (ja)
JP2017137500A5 (ja)
JP2018521020A5 (ja)
JP2019164961A5 (ja)
JP2013532130A5 (ja)
JP2019124943A5 (ja)
JP2021503553A5 (ja)
JP2018186811A5 (ja)
JP2020183924A5 (ja)
JP2018116258A5 (ja)
JP2019081810A5 (ja)
JP2011037885A5 (ja)
JP2021512134A5 (ja)
JP2020031580A5 (ja)
JP2018162319A5 (ja)
JP2018030858A5 (ja)
JP2019218238A5 (ja)